Dual VEGF/VEGFR inhibition in advanced solid malignancies: Clinical effects and pharmacodynamic biomarkers

Our prior phase I study of the combination of vascular endothelial growth factor (VEGF) antibody, bevacizumab, and VEGF receptor (VEGFR) inhibitor, sunitinib, in advanced solid tumors identified an encouraging response evaluation. An expansion phase of this study was thus undertaken to obtain furthe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Mittal, Kriti, Koon, Henry, Elson, Paul, Triozzi, Pierre, Dowlati, Afshin, Chen, Helen, Borden, Ernest C, Rini, Brian I
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Landes Bioscience 2014
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4119082/
https://ncbi.nlm.nih.gov/pubmed/24842548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.29187
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller